108 related articles for article (PubMed ID: 10822053)
1. Vasorelaxant effect of a phosphodiesterase 3 inhibitor, olprinone, on isolated human radial artery.
Adachi H; Kamata S; Kodama K; Nagakura T
Eur J Pharmacol; 2000 May; 396(1):43-7. PubMed ID: 10822053
[TBL] [Abstract][Full Text] [Related]
2. Vasorelaxant effect of olprinone, an inhibitor of phosphodiesterase 3, on mesenteric small artery and vein of rabbits.
Fujimoto S; Ohashi M; Hiramoto A; Inoue Y; Nagai K; Shiokawa H; Itoh T
Eur J Pharmacol; 1998 Jul; 353(2-3):239-46. PubMed ID: 9726653
[TBL] [Abstract][Full Text] [Related]
3. Differential vasodilation response to olprinone in rabbit renal and common carotid arteries.
Minonishi T; Ogawa K; Tokinaga Y; Negoro T; Kimoto Y; Hatano Y
J Anesth; 2010 Feb; 24(1):61-6. PubMed ID: 20175287
[TBL] [Abstract][Full Text] [Related]
4. Effects of a phosphodiesterase 3 inhibitor, olprinone, on rhythmical change in tension of human gastroepiploic artery.
Adachi H; Kakiki M; Kishi Y
Eur J Pharmacol; 2005 Dec; 528(1-3):137-43. PubMed ID: 16325808
[TBL] [Abstract][Full Text] [Related]
5. Differential pharmacologic sensitivities of phosphodiesterase-3 inhibitors among human isolated gastroepiploic, internal mammary, and radial arteries.
Onomoto M; Tsuneyoshi I; Yonetani A; Suehiro S; Matsumoto K; Sakata R; Kanmura Y
Anesth Analg; 2005 Oct; 101(4):950-956. PubMed ID: 16192501
[TBL] [Abstract][Full Text] [Related]
6. Possible mechanisms underlying the vasodilatation induced by olprinone, a phosphodiesterase III inhibitor, in rabbit coronary artery.
Ohashi M; Dohi Y; Itoh T
Br J Pharmacol; 2000 Mar; 129(5):1000-6. PubMed ID: 10696101
[TBL] [Abstract][Full Text] [Related]
7. Olprinone: a phosphodiesterase III inhibitor with positive inotropic and vasodilator effects.
Mizushige K; Ueda T; Yukiiri K; Suzuki H
Cardiovasc Drug Rev; 2002; 20(3):163-74. PubMed ID: 12397365
[TBL] [Abstract][Full Text] [Related]
8. Characterization of the phosphodiesterase inhibition by 2-(3-methoxy-5-methylsulfinyl-2-thienyl)-1H-imidazo-(4,5-c)-pyridine HCl and its sulfide- and sulfone derivatives in myocardial preparations from failing human hearts.
Bethke T; Klimkiewicz A; Meyer W; Schumacher C; Schmitz W; Scholz H; Starbatty J; Wenzlaff H; Zimmermann W
Arzneimittelforschung; 1995 Jul; 45(7):771-6. PubMed ID: 8573220
[TBL] [Abstract][Full Text] [Related]
9. Vasorelaxant effect of phosphodiesterase-inhibitor milrinone in the human radial artery used as coronary bypass graft.
He GW; Yang CQ
J Thorac Cardiovasc Surg; 2000 May; 119(5):1039-45. PubMed ID: 10788827
[TBL] [Abstract][Full Text] [Related]
10. Vasorelaxant effects of SCA40 (a phosphodiesterase III inhibitor) in pulmonary vascular preparations in rats.
Crilley TK; Wanstall JC; Bonnet PA
Clin Exp Pharmacol Physiol; 1998 May; 25(5):355-60. PubMed ID: 9612663
[TBL] [Abstract][Full Text] [Related]
11. Endothelium-dependent relaxation of rat aorta by butein, a novel cyclic AMP-specific phosphodiesterase inhibitor.
Yu SM; Cheng ZJ; Kuo SC
Eur J Pharmacol; 1995 Jun; 280(1):69-77. PubMed ID: 7498256
[TBL] [Abstract][Full Text] [Related]
12. Identification, characterization, and functional role of phosphodiesterase type IV in cerebral vessels: effects of selective phosphodiesterase inhibitors.
Willette RN; Shiloh AO; Sauermelch CF; Sulpizio A; Michell MP; Cieslinski LB; Torphy TJ; Ohlstein EH
J Cereb Blood Flow Metab; 1997 Feb; 17(2):210-9. PubMed ID: 9040501
[TBL] [Abstract][Full Text] [Related]
13. Cardiovascular effects of the new cardiotonic agent 1,2-dihydro-6-methyl-2-oxo-5-(imidazo[1,2-a]pyridin-6-yl)-3-pyridine carbonitrile hydrochloride monohydrate. 1st communication: studies on isolated guinea pig cardiac muscles.
Ogawa T; Ohhara H; Tsunoda H; Kuroki J; Shoji T
Arzneimittelforschung; 1989 Jan; 39(1):33-7. PubMed ID: 2566308
[TBL] [Abstract][Full Text] [Related]
14. Effects of saterinone and its enantiomers R(+)-saterinone and S(-)-saterinone on the phosphodiesterase isoenzymes from ventricular tissue of failing human hearts and porcine hearts.
Zimmermann W; Scholz H; Schumacher C; Wenzlaff H; Haverich A
Naunyn Schmiedebergs Arch Pharmacol; 1994 Jun; 349(6):611-8. PubMed ID: 7526225
[TBL] [Abstract][Full Text] [Related]
15. The effects of olprinone, a phosphodiesterase 3 inhibitor, on systemic and cerebral circulation.
Ueda T; Mizushige K
Curr Vasc Pharmacol; 2006 Jan; 4(1):1-7. PubMed ID: 16472171
[TBL] [Abstract][Full Text] [Related]
16. Effects of the new cardiotonic phosphodiesterase inhibitor 1,2-dihydro-5- imidazo[1,2-a]pyridin-6-yl-6-methyl-2-oxo-3-pyridine-carbonitrile hydrochloride monohydrate on aortic input impedance.
Kubota T; Itaya R; Todaka K; Sugimachi M; Sunagawa K; Takeshita A
Arzneimittelforschung; 1991 Dec; 41(12):1211-5. PubMed ID: 1815518
[TBL] [Abstract][Full Text] [Related]
17. Effects of phosphodiesterase inhibitors after coronary artery bypass grafting.
Orime Y; Shiono M; Hata H; Yagi S; Tsukamoto S; Okumura H; Kimura S; Hata M; Sezai A; Obana M; Sezai Y
Jpn Circ J; 1999 Feb; 63(2):117-22. PubMed ID: 10084374
[TBL] [Abstract][Full Text] [Related]
18. Sildenafil and T-1032, phosphodiesterase type 5 inhibitors, showed a different vasorelaxant property in the isolated rat aorta.
Mochida H; Inoue H; Takagi M; Noto T; Yano K; Kikkawa K
Eur J Pharmacol; 2002 Apr; 440(1):45-52. PubMed ID: 11959087
[TBL] [Abstract][Full Text] [Related]
19. Isoenzymes of cyclic nucleotide phosphodiesterase in the human aorta: characterization and the effects of E4021.
Miyahara M; Ito M; Itoh H; Shiraishi T; Isaka N; Konishi T; Nakano T
Eur J Pharmacol; 1995 Sep; 284(1-2):25-33. PubMed ID: 8549633
[TBL] [Abstract][Full Text] [Related]
20. [Early hemodynamic effects of olprinone hydrochloride after coronary artery bypass grafting].
Marui A; Mochizuki T; Mitsui N; Koyama T; Horibe M
Jpn J Thorac Cardiovasc Surg; 1998 Nov; 46(11):1112-6. PubMed ID: 9884561
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
